Ryan Scott


Janjigian Spotlights Significance of Nivolumab/Chemo Approval for Frontline Gastric Cancer

September 24th 2021

Yelena Y. Janjigian, MD, further discusses the clinical significance of the FDA approval of nivolumab plus chemotherapy in the frontline treatment of patients with gastric cancer.

Acalabrutinib Continues to Showcase Impressive Activity in Relapsed/Refractory MCL

September 21st 2021

Michael Wang, MD, discusses the impact of acalabrutinib in patients with mantle cell lymphoma, the implications of the phase 2 ACE-LY-004 trial, and the challenges faced with treating those who harbor TP53 mutations.

Dosing Strategies Help Personalize Care in HER2+ Breast Cancer

September 14th 2021

Sara M. Tolaney, MD, MPH, discusses progress made with escalation and de-escalation strategies in HER2-positive breast cancer, ongoing research with immunotherapy, and efforts being made to further move the needle forward.

Management of Toxicities Is Crucial to Immunotherapy Combination Use in HCC

September 7th 2021

David J. Pinato, MD, discusses combination strategies in HCC, how to manage associated toxicities, and how safety profiles can help to inform treatment decisions for this patient population.

Ongoing Research Pushes Precision Oncology Mindset in Gastrointestinal Cancers

September 6th 2021

E. Gabriela Chiorean, MD, discusses some of the recent developments in pancreatic cancer, HCC, and NETs, as well as multidisciplinary approaches for treating these patients.

PARP Inhibitors Play Key Role in Prostate Cancer Paradigm, as Hunt for Biomarkers Continues

August 31st 2021

Wassim Abida, MD, PhD, discusses the role of PARP inhibition in the treatment of patients with prostate cancer, and the importance of biomarkers in guiding treatment decisions with these agents

Investigative Directions in Ovarian Cancer Continue to Comprise Multidisciplinary Approaches

August 27th 2021

Sanaz Memarzadeh, MD, PhD, focuses on these ongoing multidisciplinary research directions aimed at improving outcomes for patients with ovarian cancer.

Next Steps With Loncastuximab Tesirine in LBCL Involve Exploring Novel Combo Regimens

August 25th 2021

Paolo F. Caimi, MD, discusses the FDA approval of loncastuximab tesirine in large B-cell lymphoma, results from the phase 2 LOTIS-2 trial, and future research directions with the agent.

Zandelisib/Zanubrutinib Produces Promising Safety, Efficacy in Relapsed/Refractory B-Cell Malignancies

August 18th 2021

Alexey V. Danilov, MD, discusses the safety and efficacy achieved with the novel combination comprised of zandelisib and zanubrutinib in patients with relapsed/refractory B-cell malignancies.

PD-1/Chemo Combos Raise the Stakes in SCLC, as Focus Shifts to Leveraging Molecular Testing

August 18th 2021

Jonathan W. Goldman, MD, discusses the significance of the phase 3 CASPIAN and IMpower133 trials in small cell lung cancer and efforts made to optimize molecular testing.

ADCs, TKIs, and More Expand Treatment Options in HER2+ Metastatic Breast Cancer

August 16th 2021

Mark D. Pegram, MD, discusses the latest data in HER2-positive metastatic breast cancer.

Fixed-Duration Ibrutinib/Venetoclax Provides Deep, Durable Responses in Frontline CLL/SLL

August 10th 2021

A fixed duration of ibrutinib plus venetoclax has demonstrated durable efficacy when used in the frontline treatment of patients with chronic lymphocytic leukemia and small lymphocytic lymphoma (SLL).

Rusfertide Could Represent New Therapeutic Option in Polycythemia Vera

August 6th 2021

Marina Kremyanskaya, MD, PhD, discussed the results of the phase 2 PTG-300-04 trial, which were presented at the European Hematology Association 2021 Virtual Congress, and the potential for rusfertide as a treatment option for patients with polycythemia vera.

Allogeneic HSCT Linked With Favorable Survival Outcomes in Myelofibrosis

August 5th 2021

Though there have been significant and recent therapeutic developments for patients with myelofibrosis, allogeneic hematopoietic stem cell transplant remains the sole curative therapeutic modality.

Pembrolizumab/Lenvatinib Under Evaluation in Frontline Non–Clear Cell RCC

August 4th 2021

Chung-Han Lee, MD, PhD, discusses the goals of the phase 3 KEYNOTE-B61 study and the potential for immunotherapy/TKI combinations in non–clear cell RCC.

Rini Remarks on Remaining Questions With Pembrolizumab/Axitinib in Frontline Advanced Clear Cell RCC

August 4th 2021

At a median follow-up of 42.8 months, frontline pembrolizumab plus axitinib continued to yield improved outcomes over sunitinib in patients with advanced clear cell renal cell carcinoma.

Predicting the Future of Overcoming EGFR Resistance Mechanisms in NSCLC

July 31st 2021

Sukhmani K. Padda, MD, discusses strategies to overcome EGFR resistance in patients with non–small cell lung cancer.

KAMILLA Data Reinforce Favorable Benefit/Risk Profile of T-DM1 in HER2+ Breast Cancer

July 28th 2021

Rachel Wuerstlein, MD, discusses the safety and the efficacy observed with ado-trastuzumab emtansine in patients with HER2-positive breast cancer and the next steps for research with the agent.

Borghaei Breaks Down the Impact of Sotorasib in KRAS G12C–Mutant NSCLC and Future Research Directions

July 27th 2021

Hossein Borghaei, DO, MS, discusses the clinical implications of the FDA approval of sotorasib in patients with KRAS G12C–mutant NSCLC.

Tisagenlecleucel Demonstrates High Rates of Durable Responses in Relapsed/Refractory Follicular Lymphoma

July 23rd 2021

The CAR T-cell product tisagenlecleucel has been shown to elicit durable responses in adult patients with relapsed/refractory follicular lymphoma with a safety profile that compares favorably with other available products.